Zacks: Brokerages Anticipate Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Will Post Earnings of -$0.60 Per Share

Brokerages expect that Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) will announce earnings per share (EPS) of ($0.60) for the current quarter, according to Zacks. Zero analysts have made estimates for Crinetics Pharmaceuticals’ earnings, with estimates ranging from ($0.67) to ($0.51). Crinetics Pharmaceuticals reported earnings of ($0.66) per share in the same quarter last year, which indicates a positive year over year growth rate of 9.1%. The firm is scheduled to report its next quarterly earnings report on Tuesday, March 29th.

According to Zacks, analysts expect that Crinetics Pharmaceuticals will report full year earnings of ($2.71) per share for the current year, with EPS estimates ranging from ($2.79) to ($2.59). For the next fiscal year, analysts expect that the company will post earnings of ($2.54) per share, with EPS estimates ranging from ($2.73) to ($2.35). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its earnings results on Friday, November 5th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.01).

CRNX has been the subject of a number of research reports. HC Wainwright raised their price objective on Crinetics Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, November 8th. Zacks Investment Research upgraded Crinetics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research report on Wednesday. Jonestrading reiterated a “buy” rating and issued a $45.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Thursday, September 16th. Finally, Evercore ISI initiated coverage on Crinetics Pharmaceuticals in a research report on Tuesday. They issued an “outperform” rating for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $34.20.

NASDAQ:CRNX traded up $0.38 during mid-day trading on Thursday, hitting $27.48. 494,348 shares of the company’s stock traded hands, compared to its average volume of 187,906. The firm’s 50 day moving average price is $23.59. Crinetics Pharmaceuticals has a 12 month low of $12.60 and a 12 month high of $28.78. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -9.88 and a beta of 1.37.

In related news, insider Stephen F. Betz sold 3,000 shares of the firm’s stock in a transaction on Wednesday, October 27th. The stock was sold at an average price of $24.00, for a total transaction of $72,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Perceptive Advisors Llc purchased 1,200,000 shares of the company’s stock in a transaction that occurred on Monday, October 25th. The shares were acquired at an average cost of $19.80 per share, with a total value of $23,760,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders sold 71,210 shares of company stock valued at $1,830,004. 7.40% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in CRNX. Advisor Group Holdings Inc. increased its holdings in Crinetics Pharmaceuticals by 222.2% during the 2nd quarter. Advisor Group Holdings Inc. now owns 1,450 shares of the company’s stock valued at $27,000 after purchasing an additional 1,000 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Crinetics Pharmaceuticals by 215.0% in the 1st quarter. Royal Bank of Canada now owns 1,786 shares of the company’s stock valued at $27,000 after buying an additional 1,219 shares during the period. Great West Life Assurance Co. Can acquired a new stake in shares of Crinetics Pharmaceuticals in the 2nd quarter valued at $27,000. Meeder Asset Management Inc. acquired a new stake in shares of Crinetics Pharmaceuticals in the 3rd quarter valued at $42,000. Finally, Marshall Wace North America L.P. acquired a new stake in shares of Crinetics Pharmaceuticals in the 1st quarter valued at $43,000. 85.05% of the stock is owned by hedge funds and other institutional investors.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly.

Featured Article: Trading Ex-Dividend Strategy

Get a free copy of the Zacks research report on Crinetics Pharmaceuticals (CRNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.